Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer

NCT00085566 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT00085566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00085566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2004
Completion date
February 29, 2008
Enrollment
61 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, prostate cancer